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Perspective
S
tandard care for HIV 
antiretroviral treatment in 
resource-rich regions of the 
world includes HIV RNA monitoring 
every three to four months for viral 
rebound (i.e., an increase in HIV 
RNA to detectable levels following 
suppression). Viral rebound conﬁ  rmed 
by two HIV RNA determinations 
prompts adherence counseling, 
and a change in regimen based on 
prior antiretroviral treatment and 
antiretroviral resistance testing. 
Because of the prohibitive cost of 
viral RNA monitoring, standard care 
for resource-limited regions of the 
world includes clinical monitoring, 
together with CD4 monitoring if it is 
available. A new WHO (World Health 
Organization) Stage IV opportunistic 
infection, a 50% decline from peak 
CD4 level, failure to increase CD4 
levels to 50–100 cells/mm3 after one 
year, or a fall in CD4 cell count to 
pretreatment levels after one year 
prompts a change to second-line 
therapy if available [1]. 
The major limitation of CD4 and 
clinical monitoring alone is that 
clinical deterioration and CD4 decline 
often occur well after virologic failure 
and the accumulation of resistance 
mutations that may compromise 
the efﬁ  cacy of limited second-line 
treatment options [16]. Conversely, 
CD4 and clinical decline can occur in 
the absence of virologic failure, which 
can prompt a premature switch to 
second-line therapy. This limitation 
has prompted a search for low-cost 
approaches to HIV RNA monitoring, 
including new surrogates of HIV RNA  
[2]. This search, however, has yet 
to yield a reliable, inexpensive, and 
scalable approach for resource-limited 
regions of the world.
Adherence Monitoring to Detect 
Viral Rebound in Resource-Limited 
Settings
In a study published in this issue of 
PLoS Medicine, Gregory Bisson and 
colleagues compared the ability of CD4 
counts and adherence to medication 
to predict virologic failure [3]. They 
conducted an observational cohort 
study involving 1,982 patients in nine 
countries in southern Africa, who were 
being treated with a non-nucleoside 
reverse transcriptase inhibitor–based 
antiretroviral regimen. Adherence was 
assessed using pharmacy claim data. 
Virologic failure was deﬁ  ned as an HIV 
RNA level of more than 1,000 copies/
ml at an initial assessment either six or 
12 months after starting combination 
antiretroviral therapy and after a 
previous undetectable viral load (less 
than 400 copies/ml). 
Pharmacy claim adherence data 
outperformed CD4 count change 
in predicting viral suppression and 
were as good as CD4 count change at 
predicting viral rebound subsequent to 
viral suppression. Bisson and colleagues 
conclude that systematic adherence 
monitoring should be considered as 
an alternative to CD4 cell monitoring 
to identify patients at high risk for 
incomplete viral suppression.
Proactive Prevention rather 
than Reactive Response to Viral 
Rebound
Real-time adherence monitoring offers 
an important strategic advantage 
to traditional approaches in both 
resource-rich and resource-limited 
regions of the world. While most 
patients achieve initial viral suppression 
with current antiretroviral regimens, 
eventual viral rebound is common as 
adherence declines over time  [4–6]. 
Modest declines or even complete 
lapses in adherence are rarely detected 
in advance of viral rebound. Rather, 
viral rebound is usually detected 
during routine laboratory monitoring 
after lapses in adherence. Regimens 
prescribed in response to viral rebound 
are often more complex than the initial 
regimen and can lead to a continuous 
loop of less effective, poorly tolerated 
therapies that may require even higher 
levels of adherence to sustain viral 
suppression [7]. Bisson and colleagues’ 
new study supports Robert Gross and 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Bisson GP, Gross R, Bellamy S, Chittams 
J, Hislop M, et al. (2008) Pharmacy reﬁ  ll 
adherence compared with CD4 count 
changes for monitoring HIV-infected 
adults on antiretroviral therapy. PLoS 
Med 5(5): e109. doi:10.1371/journal.
pmed.0050109
Analyzing pharmacy and laboratory 
records from 1,982 patients beginning 
HIV therapy in southern Africa, Gregory 
Bisson and colleagues ﬁ  nd medication 
adherence superior to CD4 count 
changes in identifying treatment failure.PLoS Medicine  |  www.plosmedicine.org 0696 May 2008  |  Volume 5  |  Issue 5  |  e111
colleagues’ earlier proof-of-concept 
data, which suggested that that a more 
effective approach might be to focus on 
continuous adherence monitoring with 
a goal of intervening before HIV RNA 
rebounds and resistance mutations 
accumulate [8].
Improving Precision in Adherence 
Monitoring
While Bisson and colleagues suggest 
that a switch from biologic to 
behavioral monitoring may be the 
preferred monitoring strategy in 
resource-limited settings, it is unclear 
if pharmacy reﬁ  ll measures will be 
sufﬁ  ciently precise and/or time 
sensitive to proactively predict, and 
therefore prevent, viral rebound. 
Pharmacy reﬁ  ll adherence measures 
have been closely associated with viral 
suppression, drug resistance, and 
death in several studies [9–11]. The 
drug possession ratio, calculated by the 
number of doses dispensed divided 
by the number of doses prescribed in 
the interval between dispensing dates, 
has a scale of 0 to 1 (or 0% to 100%), 
where 1 (or 100%) represents the 
maximum level of adherence possible 
for a given patient. Because actual 
adherence is less than or at most equal 
to the drug possession ratio, pharmacy 
reﬁ  ll adherence information will not 
detect all patients with viral rebound. 
In addition, since medications are 
prescribed every month (sometimes 
less frequently), and viral rebound 
can occur in a matter of weeks, 
monthly pharmacy dispensing data 
may also not be sufﬁ  ciently time 
sensitive to preemptively predict viral 
rebound. Finally, pharmacy reﬁ  ll 
measures cannot differentiate patterns 
of adherence, such as treatment 
interruption, which may be more risky 
for non-nucleoside reverse transcriptase 
inhibitor resistance than a longer run 
of occasional missed doses [12,13].
There are several strategies that 
may move us closer to more accurate 
adherence monitoring. Electronic 
medication pill box organizers have 
been introduced, with encouraging 
results [14]. Cell phones, widely 
available in resource-limited settings, 
are being tested to promote health 
behaviors in many regions of the 
world  [15]. Cell phone adherence 
monitoring systems, however, often 
require a patient to respond to a 
reminder message to conﬁ  rm they 
took their dose. Systems that require 
a patient-initiated response to detect 
the health behavior in question (i.e., 
taking a dose), may suffer from patient 
habituation to the reminder, and will 
fail in patients who are nonadherent 
to the measurement strategy, which 
may be the same patients who miss 
their medication. Electronic pill 
container devices, and more recently 
wireless devices, overcome some of 
these difﬁ  culties. While such systems 
are currently prohibitively expensive 
in resource-limited settings, current 
user fees are comparable to viral 
load monitoring, and wide-scale 
implementation could reduce costs 
several-fold.
Antiretroviral treatment has 
transformed HIV from a terminal to 
a chronic disease in many regions 
of the world. Despite this important 
advance, relatively little progress has 
been made in monitoring missed 
doses, which are the proximal event 
to viral rebound and drug resistance. 
The report by Bisson and colleagues 
provokes a potential paradigm shift 
away from reactively responding to 
proactively preventing antiretroviral 
drug resistance.  
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